Trial Profile
A Phase IB, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Patients With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care Antibiotics
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Dec 2020
Price :
$35
*
At a glance
- Drugs DSTA 4637S (Primary) ; Antibacterials
- Indications Bacteraemia; Methicillin-resistant Staphylococcus aureus infections
- Focus Adverse reactions
- Sponsors Genentech
- 25 Oct 2020 Results comparing Pharmacokinetics of DSTA4637S in Patients with Staphylococcus aureus Bacteremia Receiving Standard-of-Care Antibiotics with Pharmacokinetics in Healthy Volunteers, presented at the IDWeek 2020
- 25 Oct 2020 Results presented at the IDWeek 2020
- 21 Jan 2020 Status changed from active, no longer recruiting to completed.